


Name of Company: Boehringer Ingelheim		Statement on discontinuation of the study	 Boehringer Ingelheim
BI Proprietary Name: NA		EudraCT No.: 2005-004957-89	
BI Investigational Product: BI 730357		Page: 1	
Report Date: NA	Trial No. / Doc. No.: 1407-0004	Dates of Trial: NA	Date of Revision: NA
<p align="center">Proprietary confidential information</p> <p>© 2023 Boehringer Ingelheim International GmbH or one or more of its affiliated companies. All rights reserved. This document may not - in full or in part - be passed on, reproduced, published or otherwise used without prior written permission</p>			
Title of Trial:	A Phase II, randomised, double-blind, placebo-controlled, parallel-group, dose-ranging, proof-of-concept trial of BI 730357 given for 12 weeks in patients with active psoriatic arthritis		
Trial Sites:	NA		
Publications:	NA		
Clinical Phase:	II		
Statement on discontinuation of the study:	Discontinued by Boehringer Ingelheim during preparation of the trial. No subject / patient randomized into the study, therefore no results / data are available.		